CJC-1295 + Ipamorelin + Tesamorelin
The CJC-1295 (no DAC) + Ipamorelin + Tesamorelin blend — sometimes abbreviated 'CIT' on certificates — is a research combination of three growth-hormone secretagogues that stimulate endogenous GH release through two complementary pituitary pathways (GHRH and the ghrelin receptor); research protocols typically inject the blend once nightly subcutaneously while fasted.
In the 40 mg vial (10 mg CJC-1295 / 10 mg Ipamorelin / 20 mg Tesamorelin in 2 mL) the ladder keeps CJC-1295 and Ipamorelin inside their own ranges: 2 units (CJC-1295 0.1 · Ipamorelin 0.1 · Tesamorelin 0.2 mg) to 4 units (0.2 · 0.2 · 0.4 mg), so Tesamorelin stays below its 1 mg starting dose.
Best for
Adults exploring, in a research context, endogenous growth-hormone and IGF-1 support for body-composition and visceral-fat interest. Because it stacks three active GH-axis peptides, it is not a sensible first peptide — physician guidance is strongly advised, and anyone with the GH-pathway contraindications below should avoid it.
What to expect
Plasma GH typically rises within roughly 30–60 minutes of injection (the GHRH/ghrelin pulse). Downstream IGF-1 changes are studied over days to weeks, and Tesamorelin's visceral-fat effects are measured on imaging over roughly 12–24 weeks of consistent nightly use.
Pairs with
This is already a complete three-way GH-axis stack (GHRH analog + short GHRH analog + ghrelin-receptor agonist), so adding further GH secretagogues is usually redundant and stacks side-effect risk. It is generally run standalone.
Reconstitute the 40 mg vial with 2 mL bacteriostatic water and inject subcutaneously once nightly at bedtime.
Each unit carries 0.05 mg CJC-1295, 0.05 mg Ipamorelin and 0.1 mg Tesamorelin, and the three cannot be dosed apart — so the ladder is set by the microgram-scale components' own ranges: 2 units to start (CJC-1295 0.1 · Ipamorelin 0.1 · Tesamorelin 0.2 mg) and 4 units at the top (0.2 · 0.2 · 0.4 mg, CJC-1295's 200 mcg top). Dosing to Tesamorelin's 1–2 mg instead (10–20 units) would mean 0.5–1 mg each of CJC-1295 and Ipamorelin, 2.5–5x and 1.7–3.3x their own tops.
Draws this small are easiest to read on a 0.3 mL (30-unit) syringe. Inject fasted — no food for ~2 hours before and shortly after — so an insulin/glucose spike does not blunt the GH pulse.
Bedtime timing aligns the pulse with the natural overnight GH surge.
- How often
- Daily
- When
- Bedtime, fasted
- Route
- Subcutaneous
- Vial & water
- 40 mg in 2 mL · 2 units ≈ 0.2 mg Tesamorelin + 0.1 mg CJC-1295 (no DAC) + 0.1 mg Ipamorelin
- Cycle
- Run in blocks (commonly ~12–16 weeks), then a break to preserve GH-receptor and GHSR sensitivity — not indefinitely continuous.
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
This blend combines three synthetic growth-hormone secretagogues that raise GH through complementary mechanisms rather than delivering GH directly.
Tesamorelin is a stabilized 44-amino-acid analog of growth-hormone-releasing hormone (GHRH) with an N-terminal trans-3-hexenoic-acid modification that extends its half-life well beyond endogenous GHRH's ~7-minute window; it is FDA-approved (as Egrifta) for HIV-associated lipodystrophy and is the most clinically validated component, driving 15–20% reductions in visceral-fat area over 26 weeks in its pivotal trials by preferentially mobilizing deep abdominal fat. CJC-1295 (no DAC), also called modified GRF (1-29), is a synthetic analog of the first 29 residues of GHRH that binds the same GHRH receptor on pituitary somatotrophs, raising intracellular cAMP; its short half-life is chosen to approximate natural pulsatile release.
Ipamorelin is a selective pentapeptide agonist of the ghrelin / growth-hormone-secretagogue receptor (GHSR-1a) — a distinct receptor from GHRH — and is prized for stimulating a clean GH pulse without the cortisol, ACTH, or prolactin elevations seen with older GHRPs. Pairing a GHRH-pathway agonist with a ghrelin-receptor agonist is studied as a way to amplify total GH output through two independent receptors, while the Tesamorelin component adds a longer, visceral-fat-directed GHRH signal.
Of the three, only Tesamorelin is FDA-approved; CJC-1295 (no DAC) and Ipamorelin are handled as research compounds, and controlled human data on the specific three-way combination are lacking.
References3
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.